Display Settings:

Format

Send to:

Choose Destination

    EMBO J. 2007 Nov 14;26(22):4768-76. Epub 2007 Oct 18.

    Structural basis for the recruitment of ERCC1-XPF to nucleotide excision repair complexes by XPA.

    Tsodikov OV, Ivanov D, Orelli B, Staresincic L, Shoshani I, Oberman R, Schärer OD, Wagner G, Ellenberger T.

    Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA.

    The nucleotide excision repair (NER) pathway corrects DNA damage caused by sunlight, environmental mutagens and certain antitumor agents. This multistep DNA repair reaction operates by the sequential assembly of protein factors at sites of DNA damage. The efficient recognition of DNA damage and its repair are orchestrated by specific protein-protein and protein-DNA interactions within NER complexes. We have investigated an essential protein-protein interaction of the NER pathway, the binding of the XPA protein to the ERCC1 subunit of the repair endonuclease ERCC1-XPF. The structure of ERCC1 in complex with an XPA peptide shows that only a small region of XPA interacts with ERCC1 to form a stable complex exhibiting submicromolar binding affinity. However, this XPA peptide is a potent inhibitor of NER activity in a cell-free assay, blocking the excision of a cisplatin adduct from DNA. The structure of the peptide inhibitor bound to its target site reveals a binding interface that is amenable to the development of small molecule peptidomimetics that could be used to modulate NER repair activities in vivo.

    PMID: 17948053 [PubMed - indexed for MEDLINE]

    PMCID: 2080803

    Supplemental Content

    Click here to read Click here to read

    Structures reported by this article

    Patient drug information

    • Cisplatin (Platinol®-AQ)

      Your doctor has ordered the drug cisplatin to help treat your illness. The drug is given by injection into a vein.